Facts & Figures
Science for a better life - Medical Progress for the Benefit of the Patient
Facts and Figures at a glance
|Research expenses 2014||2,297 € million (2013: 2,039 € million)|
|Proportion of total Bayer group research expenses 2014||64.4%|
|Employees in Research & Development||8,100|
|Main research locations||Berlin and Wuppertal, Germany, Berkeley, USA, Bejing, China
Research activities 2014
Research and development expenses at HealthCare rose by 3.6% (Fx adj.) in 2014 to €2,301 million. Adjusted for special items of €4 million (2013: €190 million), this represented a 13.0% increase (Fx adj.) and was equivalent to 11.5% of HealthCare sales. At the end of the reporting period there were 8,100 employees working in research and development at HealthCare.
Research areas and sites
Drug discovery in the Pharmaceuticals segment focuses on the areas of cardiology, oncology, ophthalmology, hematology and gynecology. We conduct research activities at six centers. Work in Berlin and Wuppertal, Germany, focuses on the discovery, optimization and development of new active substances. Research is also carried out at these sites in the fields of drug metabolism, pharmacokinetics, toxicology and clinical pharmacology. On the other hand, our u.s. research and development activities in the Mission Bay district of San Francisco and in Berkeley, California, are focused on hematology. In Turku, Finland, polymer-based release systems are being developed for fertility control. At our site in Oslo, Norway, we are carrying out research on Thorium Conjugate for use in cancer. We also operate innovation centers in Beijing, China; Singapore; and Osaka, Japan, which focus on coordinating our research partnerships in Asia.
We conducted clinical trials with several drug candidates from our research and development pipeline during 2014 to drive the development of new substances for treating diseases with a high unmet medical need. At the focus of our clinical development are five active substance candidates currently in Phase II trials. These are Finerenone, Vericiguat and Molidustat in the cardiology and cardiorenal syndrome areas, Copanlisib in oncology and Vilaprisan in gynecology. We strengthen our already approved products, such as the anticoagulant Xarelto™ (Rivaroxaban), the cancer drugs Stivarga™ (Regorafenib) and Xofigo™ (radium-223 dichloride), the eye medicine Eylea™ (Aflibercept) and Adempas™ (Riociguat) for treatment of pulmonary hypertension, through life cycle management activities in order to further enhance their use and/or expand their spectrum of indications.
Some of our development candidates are being investigated for the treatment of illnesses that are serious but at the same time very rare – also known as orphan diseases. For example, ciprofloxacin dpi (dry powder for inhalation) for therapy of non-cystic-fibrosis bronchiectasis (NCFB) was classified by the regulatory authorities as an orphan drug.
In our Consumer Care Division, research and development activities at the product development centers in Morristown, New Jersey and Memphis, Tennessee, United States, and Gaillard, France, focus on developing non-prescription medicines, medical skincare products, foot care products, sunscreens and nutritional supplements to market maturity. Aligned to end consumers, our development strategies are geared toward expanding and improving our brand portfolio through new products and delivery forms. We also work to achieve reclassification of current prescription medicines as OTC products. We introduced a number of new product line expansions to various markets in 2014. They included new delivery forms and uses for existing brands such as Canesten™, Bepanthen™/Bepanthol™, Coppertone™ and Dr. Scholl’s™.
The research and development activities of our Medical Care Division focus on blood glucose monitoring and the continuing development of contrast agents and medical equipment used in the diagnosis or treatment of various diseases.
At our two US. research and development locations for the Diabetes Care business unit – Tarrytown, New York, and Mishawaka, Indiana – we are focusing on strengthening our product lines. Among the innovative products we launched in key markets in 2014 was the Contour™ ts platform in Europe.
The aim of our research and development activities in the area of contrast agents and medical equipment (Radiology business unit) is to steadily improve our contrast agents and our contrast injection systems in order to build on our leadership position. Our research and development centers are located near Pittsburgh, Pennsylvania, United States; in Toronto, Canada; in Berlin, Germany; and in Sydney, Australia. In June 2014, Gadavist™ (Gadobutrol) was approved by the FDA as the first contrast agent in magnetic resonance imaging (MRI) for detection and evaluation of breast cancer. In January 2015, Gadavist™ was the first contrast agent to receive FDA approval for use in children under two years of age. In 2014 we also worked to expand the capabilities of our informatics product offerings by developing new software and informatics to improve contrast agent and radiation dose management.
In our Animal Health Division, we focus our research and development activities on antiparasitics, antibiotics and medicines to treat non-infectious disorders. We operate R&D centers in Germany, the United States, New Zealand and Brazil. Our central research activities are conducted in Monheim, Germany, as part of our Life Sciences platform in conjunction with pharmaceutical research and in close collaboration with our researchers at CropScience. We reinforce the business by continually identifying further product development candidates through our existing collaborations.